Palliative care physicians' recognition of patients after immune checkpoint inhibitors and immune-related adverse events.
Cross-sectional survey
Immune checkpoint inhibitors
Immune-related adverse events
Palliative care physicians
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
10
03
2021
accepted:
29
07
2021
pubmed:
13
8
2021
medline:
15
12
2021
entrez:
12
8
2021
Statut:
ppublish
Résumé
This study investigated the experience of palliative care physicians (PCPs) and their knowledge and recognition of immune checkpoint inhibitors (ICIs) and immune-related adverse events (irAEs) in clinical practice as well as the need to provide palliative care services for patients after ICI treatments. A cross-sectional survey with self-administered questionnaires was conducted between February and April 2020. A total of 759 questionnaires were sent to PCPs in Japan. The changes in the PCPs' knowledge and recognition of ICIs and irAEs due to the increased experiences of treating patients after ICI treatments were analyzed. Four hundred ninety-two responses (64.8%) were analyzed. Only 15.0% of respondents had no experience of patients after ICI treatments, while 53.9% had experience of more than six patients. On the other hand, 40% of respondents had no experience of patients with suspected irAEs, while only 13.4% had experience of more than six patients. Respondents with more experience of patients after ICI treatments or those with suspected irAEs had extensive knowledge of ICIs and irAEs, were more confident in treating these patients, and tended to consider irAEs as therapeutic indications. The majority of respondents required guidelines and efficient consultation systems with oncologists. This study demonstrated that PCPs with experience had extensive knowledge and confidence of ICIs and irAEs and tended to recognize irAEs as therapeutic indications. The establishment of a more intimate relationship between PCPs and oncologists is important for providing better treatment for these patients.
Identifiants
pubmed: 34383113
doi: 10.1007/s00520-021-06482-5
pii: 10.1007/s00520-021-06482-5
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
775-784Subventions
Organisme : Ministry of Health, Labour and Welfare
ID : 19EA1011
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
doi: 10.1056/NEJMoa1003466
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330
doi: 10.1056/NEJMoa1412082
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34
doi: 10.1056/NEJMoa1504030
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135
doi: 10.1056/NEJMoa1504627
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639
doi: 10.1056/NEJMoa1507643
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA (2017) First-line nivolumab in stage iv or recurrent non-small-cell lung cancer. N Engl J Med 376:2415–2426
doi: 10.1056/NEJMoa1613493
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016) Pembrolizumab versus chemotherapy for pd-l1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833
doi: 10.1056/NEJMoa1606774
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813
doi: 10.1056/NEJMoa1510665
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015–1026
doi: 10.1056/NEJMoa1613683
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867
doi: 10.1056/NEJMoa1602252
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538–12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 390:2461–2471
doi: 10.1016/S0140-6736(17)31827-5
Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab Journal of clinical oncology : official journal of the American Society of. Clin Oncol 30:2691–2697
Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR (2015) A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors Annals of oncology : official journal of the European Society for. Med Oncol 26:1824–1829
Rapoport BL, Anderson R, Cooksley T, Johnson DB (2020) MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 28:6107–6110
doi: 10.1007/s00520-020-05727-z
Cooksley T, Gupta A, Al-Sayed T (1990) Lorigan P (2020) Emergency presentations in patients treated with immune checkpoint inhibitors European journal of cancer (Oxford. England 130:193–197
El Majzoub I, Qdaisat A, Thein KZ, Win MA, Han MM, Jacobson K, Chaftari PS, Prejean M, Reyes-Gibby C, Yeung SJ (2019) Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. Ann Emerg Med 73:79–87
doi: 10.1016/j.annemergmed.2018.04.019
Rapoport BL, Cooksley T, Johnson DB, Anderson R (2021) Supportive care for new cancer therapies. Curr Opin Oncol 33:287–294
doi: 10.1097/CCO.0000000000000736
De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK (2017) Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 5:312–318
doi: 10.1158/2326-6066.CIR-16-0237
Blidner AG, Choi J, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL (2020) Cancer immunotherapy-related adverse events: causes and challenges. Support Care Cancer 28:6111–6117
doi: 10.1007/s00520-020-05705-5
Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology 28:iv119–iv142
doi: 10.1093/annonc/mdx225
Liao G, Wang Z, Li H, Min J, Zhong J, Mariella S, Qian K, Zhang W (2019) Learning curve and short-term outcomes of modularized LADG for advanced gastric cancer: a retrospective study. Medicine 98:e14670
doi: 10.1097/MD.0000000000014670
Kim CY, Nam BH, Cho GS, Hyung WJ, Kim MC, Lee HJ, Ryu KW, Ryu SW, Shin DW, Lee JH (2016) Learning curve for gastric cancer surgery based on actual survival. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 19:631–638
doi: 10.1007/s10120-015-0477-0
Lin CK, Lai CL, Chang LY, Wen YF, Ho CC (2018) Learning curve and advantages of endobronchial ultrasound-guided transbronchial needle aspiration as a first-line diagnostic and staging procedure. Thorac Cancer 9:75–82
doi: 10.1111/1759-7714.12539
da Silva GFM, Landim J (2020) Knowledge gap about immune checkpoint inhibitors among rheumatologists and medical students: a survey. Rheumatol Int 41:939–942
doi: 10.1007/s00296-020-04674-6
Kostine M, Cappelli LC, Calabrese C (2019) Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists? Ann Rheum Dis 78:860–862
doi: 10.1136/annrheumdis-2018-214748
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742
doi: 10.1056/NEJMoa1000678
Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighl N, Oza A, Moore M, Rydall A, Rodin G, Tannock I, Donner A, Lo C (2014) Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet (London, England) 383:1721–1730
doi: 10.1016/S0140-6736(13)62416-2
Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, Hull JG, Li Z, Tosteson TD, Byock IR, Ahles TA (2009) Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. Jama 302:741–749
doi: 10.1001/jama.2009.1198
Hui D, Kim SH, Roquemore J, Dev R, Chisholm G, Bruera E (2014) Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients. Cancer 120:1743–1749
doi: 10.1002/cncr.28628
Von Roenn JH, Voltz R, Serrie A (2013) Barriers and approaches to the successful integration of palliative care and oncology practice. Journal of the National Comprehensive Cancer Network : JNCCN 11(Suppl 1):S11-16
doi: 10.6004/jnccn.2013.0209
Kaasa S, Loge JH, Aapro M, Albreht T, Anderson R, Bruera E, Brunelli C, Caraceni A, Cervantes A, Currow DC, Deliens L, Fallon M, Gómez-Batiste X, Grotmol KS, Hannon B, Haugen DF, Higginson IJ, Hjermstad MJ, Hui D, Jordan K, Kurita GP, Larkin PJ, Miccinesi G, Nauck F, Pribakovic R, Rodin G, Sjøgren P, Stone P, Zimmermann C, Lundeby T (2018) Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncol 19:e588–e653
doi: 10.1016/S1470-2045(18)30415-7
Nickolich MS, El-Jawahri A, Temel JS, LeBlanc TW (2016) Discussing the evidence for upstream palliative care in improving outcomes in Advanced Cancer. Am Soc Clin Oncol Educ Book 35:e534-538 (American Society of Clinical Oncology Annual Meeting)
doi: 10.1200/EDBK_159224
Riedel RF, Slusser K, Power S, Jones CA, LeBlanc TW, Kamal AH, Desai D, Allen D, Yu Y, Wolf S, Galanos AN (2017) Improvements in patient and health system outcomes using an integrated oncology and palliative medicine approach on a solid tumor inpatient service. J Oncol Pract 13:e738–e748
doi: 10.1200/JOP.2017.022749